We are live on ! Find out more
AVTX icon

Avalo Therapeutics
AVTX

19 hedge funds and large institutions have $28M invested in Avalo Therapeutics in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

52% more capital invested

Capital invested by funds: $18.4M → $28M (+$9.56M)

6% more funds holding

Funds holding: 18 → 19 (+1)

0% more ownership

Funds ownership: 0.25% → 0.25% (+0%)

0% more call options, than puts

Call options by funds: $1K | Put options by funds: $1K

80% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 5

Holders
19
Holders Change
+1
Holders Change %
+5.56%
% of All Funds
0.31%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
5
Closed
1
Calls
$1K
Puts
$1K
Net Calls
–
Net Calls Change
-$6K

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$102K
2
Morgan Stanley
Morgan Stanley
New York
+$5.21K
3
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$2.61K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$43K
2
NCM
Nantahala Capital Management
Connecticut
-$39.1K
3
Goldman Sachs
Goldman Sachs
New York
-$14.3K
4
UBS Group
UBS Group
Switzerland
-$2.61K
5
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
-$2.38K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$20M – – –
NCM
2
Nantahala Capital Management
Connecticut
$2.73M -$39.1K -30 -1%
Point72 Asset Management
3
Point72 Asset Management
Connecticut
$2.52M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$1.12M – – –
BlackRock
5
BlackRock
New York
$520K -$1.3K -1 -0.2%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$261K – – –
Millennium Management
7
Millennium Management
New York
$220K -$43K -33 -15%
Goldman Sachs
8
Goldman Sachs
New York
$167K -$14.3K -11 -7%
State Street
9
State Street
Massachusetts
$131K – – –
Susquehanna International Group
10
Susquehanna International Group
Pennsylvania
$95K +$102K +78 New
Assenagon Asset Management
11
Assenagon Asset Management
Luxembourg
$79K – – –
Morgan Stanley
12
Morgan Stanley
New York
$62.6K +$5.21K +4 +8%
Northern Trust
13
Northern Trust
Illinois
$54.7K – – –
UBS Group
14
UBS Group
Switzerland
$31.1K -$2.61K -2 -7%
MAM
15
Meeder Asset Management
Ohio
$7.59K – – –
Royal Bank of Canada
16
Royal Bank of Canada
Ontario, Canada
$2K +$2.61K +2 New
TWA
17
TCI Wealth Advisors
Arizona
$1.26K – – –
Group One Trading
18
Group One Trading
Illinois
$931 – – –
Wells Fargo
19
Wells Fargo
California
$660 – – –
CA
20
Clearstead Advisors
Ohio
$136 – – –
Fidelity Investments
21
Fidelity Investments
Massachusetts
$66 – – –
Bank of America
22
Bank of America
North Carolina
$50 – – –
NFSG
23
Newbridge Financial Services Group
Florida
$50 – – –
PNC Financial Services Group
24
PNC Financial Services Group
Pennsylvania
$30 – – –
KTC
25
Kistler-Tiffany Companies
Pennsylvania
$10 – – –
1
2

AVTX Hedge Fund Activity: Q4 2022 in Review

19 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q4 2022, worth a combined $28M — up 52% from $18.4M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new AVTX positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 5 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $102K. The largest seller was Millennium Management, cutting an estimated $43K.

  • 19 institutional investors held Avalo Therapeutics (AVTX) as of Q4 2022, up from 18 in Q3 2022.
  • Funds reported $28M of Avalo Therapeutics stock for Q4 2022, up 52% quarter-over-quarter.
  • 2 funds opened new Avalo Therapeutics positions in Q4 2022 and 1 closed out, a net change of +1 holder.
  • The largest Avalo Therapeutics buyer in Q4 2022 was Susquehanna International Group, an estimated $102K added.
  • The largest Avalo Therapeutics seller in Q4 2022 was Millennium Management, an estimated $43K sold.

Based on aggregated 13F filings for Q4 2022.